This is the FDA’s year to shine, but can biopharma keep up as regulators continue to rev up chart-topping numbers?

The year isn’t quite over yet, but it’s clear that the FDA is giving itself high marks for productivity and overall performance for 2018. And they probably won’t get much pushback from the industry on that score, where the approval rating for agency commissioner Scott Gottlieb continues to run sky high after his first full year in that position.